CTR20262897 Albipagrastim alfa Bone marrow depression Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20262897 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 5 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20262897 is a hot trial to watch
Bone marrow depression is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20262897 is notable because it evaluates Albipagrastim alfa in a Phase 2 design sponsored by Qilu Pharmaceutical Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20262897 |
| Official title | 评价迈粒生®在儿童实体瘤参与者中的II期临床研究 |
| Phase / status | Phase 2 / 进行中 （尚未招募） |
| Intervention | Albipagrastim alfa |
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | |
| Endpoint time frame | 第一次（和/或第三次）化疗结束后 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 2 study of Albipagrastim alfa in Bone marrow depression.
Allocation is 非随机化, masking is 开放, and the intervention model is 单臂试验. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (第一次（和/或第三次）化疗结束后) — 第1化疗周期（和/或第3化疗周期）PK参数：AUC0-t、AUC0-∞、Cmax、Tmax、t1/2、CL/F、Vd/F 等。
- Primary endpoint (第一次（和/或第三次）化疗结束后) — 第1化疗周期（和/或第3化疗周期）中性粒细胞绝对计数（ANC）最低值
- Primary endpoint (第一次（和/或第三次）化疗结束后) — 第1化疗周期（和/或第3化疗周期）开始给予化疗药物至ANC最低值的时间
- Primary endpoint (第一次（和/或第三次）化疗结束后) — 第1化疗周期（和/或第3化疗周期）ANC从最低值恢复至≥0.5×10^9/L的时间
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Albipagrastim alfa is indexed as No normalized modality returned, with target No normalized target returned, mechanism No normalized mechanism returned, and global highest development status No normalized global status returned.
Company & Deal Intelligence MCP profile: Qilu Pharmaceutical Co., Ltd. is resolved to a normalized organization record in Jinan, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20262897 provides a focused lens on Bone marrow depression development. Its value will be determined by whether Albipagrastim alfa can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
